Neos Therapeutics Statement: COVID-19 Update
March 30 2020 - 8:00AM
Jerry McLaughlin, President and CEO, made the following statement:
We want to share the steps we are taking to ensure healthcare
providers and patients continue to receive support from Neos
Therapeutics and that we are doing our part to ensure our whole
team, and the patients we serve, are safe during the COVID-19
global pandemic.
To help slow the spread of COVID-19, most of our employees have
been operating under a work from home policy in accordance with
guidance issued by the Centers for Disease Control and Prevention
(CDC), the World Health Organization (WHO) and state and local
authorities. As such, our sales representatives are not visiting
provider offices, which we believe is a necessary step to help
protect patient health and facilitate providers’ attention to
direct patient care during this challenging situation.
Effective March 30, 2020, our organization, with the exception
of a limited number of essential roles, will be operating under a
reduction in hours or, in certain cases, furlough for approximately
4 weeks. We will continue to provide benefits, including medical,
to all affected employees during this period.
Neos currently markets Adzenys XR-ODT®, Cotempla XR-ODT®,
Adzenys-ER® for the treatment of ADHD and Generic Tussionex. All of
our products are available to patients, and we have approximately 4
months of inventory on hand to meet market demand. Neos continues
to closely monitor supply levels and will work diligently to
mitigate disruption to patients, should any arise. Our Neos
RxConnect patient support program remains operational and available
to all commercially ensured patients. If providers or patients have
questions, please call 1-877-875-6590.
We continue to expect that the Phase 1 ascending dose study of
NT0502 will be initiated in the second half of 2020. We will
provide an update if this timeline is impacted by COVID-19.
We are committed to continuing to implement measures intended to
minimize any potential business impact from COVID-19,
including implementing cost cutting measures, and we will continue
to closely monitor, assess and respond to the situation as it
evolves.
Contacts:
Richard EisenstadtChief Financial OfficerNeos Therapeutics,
Inc.(972) 408‑1389reisenstadt@neostx.com
Sarah McCabeStern Investor Relations, Inc.(212)
362‑1200sarah.mccabe@sternir.com
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Neos Therapeutics (NASDAQ:NEOS)
Historical Stock Chart
From Sep 2023 to Sep 2024